Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13226771 | 1.00 | CES2 (0.46) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL15259279 | 1.00 | CES2 (0.46) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL13154532 | 0.97 | CES2 (0.42) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL16350546 | 0.95 | CES2 (0.50) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL253658 | 0.95 | CES2 (0.43) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL26376485 | 0.91 | CES2 (0.44) | CES2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL13034773 | 0.90 | CES2 (0.43) | CES2MEN1KMT2AFAAHGLP1R | |
| SCHEMBL17697227 | 0.90 | CES2 (0.49) | CES2EPHX2FAAHGLP1RTSHR | |
| SCHEMBL72044 | 0.90 | CES2 (0.42) | CES2MEN1KMT2AEPHX2FAAH | |
| SCHEMBL13113388 | 0.90 | CES2 (0.42) | CES2MEN1KMT2AEPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3985002-A1 | ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20170354713-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK AS (DK) | 2017-12-14 | — | — | US | disclosed |
| US-9732137-B2 | Semi-recombinant preparation of GLP-1 analogues | NOVO NORDISK A/S (DK) | 2017-08-15 | — | — | US | disclosed |
| US-9708383-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-07-18 | — | — | US | disclosed |
| US-9409966-B2 | Glucagon-like peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK A/S (DK) | 2016-08-09 | — | — | US | disclosed |
| US-9067977-B2 | Peptides derivatized with A-B-C-D- and their therapeutical use | NOVO NORDISK A/S (DK) | 2015-06-30 | — | — | US | disclosed |
| US-9056138-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2015-06-16 | — | — | US | disclosed |
| US-20150025003-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK AS (DK) | 2015-01-22 | — | — | US | disclosed |
| US-8895694-B2 | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK A/S (DK) | 2014-11-25 | — | — | US | disclosed |
| US-20140205545-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | DYAX CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20110286929-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2011-11-24 | — | — | US | disclosed |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2011-04-07 | — | — | US | disclosed |
| US-7910088-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO SUISSE SA (CH) | 2011-03-22 | — | — | US | disclosed |
| US-7854919-B2 | Multivalent constructs for therapeutic and diagnostic applications | Bracco, Suisse SA (CH) | 2010-12-21 | — | — | US | disclosed |
| US-7666979-B2 | polyvalent targeting ligands that bind to cells used for diagnosis of diseases sensitivity to angiogenesis factor | BRACCO INTERNATIONAL B.V. (NL) | 2010-02-23 | — | — | US | disclosed |
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-10-18 | — | — | US | disclosed |
| US-7261876-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL BV (NL) | 2007-08-28 | — | — | US | disclosed |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | BRACCO INTERNATIONAL B.V. (NL) | 2007-07-26 | — | — | US | disclosed |
| US-7211240-B2 | Multivalent constructs for therapeutic and diagnostic applications | BRACCO INTERNATIONAL B.V. (NL) | 2007-05-01 | — | — | US | disclosed |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | ARBOGAST CHRISTOPHE (FR) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025003-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | CES2 4358/4885MEN1 2368/4885KMT2A 3521/4885 |
| US-20140205545-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | CES2 2949/4885MEN1 202/4885KMT2A 2522/4885 |
| US-20070243139-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | CES2 2949/4885MEN1 202/4885KMT2A 2522/4885 |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | CES2 4358/4885MEN1 2368/4885KMT2A 3521/4885 |
| US-20110286929-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | CES2 2949/4885MEN1 202/4885KMT2A 2522/4885 |
| US-20170354713-A1 | FGF21 Derivatives and Uses Thereof | FGF2, FGFR1, FGF1 | CES2 2735/4885MEN1 2805/4885KMT2A 4633/4885 |
| US-20070172428-A1 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | CD47, BCR, CD44 | CES2 2949/4885MEN1 202/4885KMT2A 2522/4885 |
| US-20040210041-A1 | Multimeric proteins for use in the treatment and detection of cell proliferative disorders | MKI67, TP53, VHL | CES2 4733/4885MEN1 1320/4885KMT2A 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.